This comprehensive analysis of clinical trials found that psilocybin, a compound found in certain mushrooms, shows promise as a treatment for depression compared to placebo. The treatment was particularly effective for patients with depression related to serious illness, those using self-reported symptom assessments, older adults, and those with prior experience with psychedelics. While side effects were minimal and temporary, researchers emphasize that more research is needed to fully understand how expectancy and individual factors influence treatment outcomes.